Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 192

1.

Thrombin-activatable fibrinolysis inhibitor and the risk for recurrent venous thromboembolism.

Eichinger S, Schönauer V, Weltermann A, Minar E, Bialonczyk C, Hirschl M, Schneider B, Quehenberger P, Kyrle PA.

Blood. 2004 May 15;103(10):3773-6. Epub 2004 Jan 22.

2.

Absolute risk of venous and arterial thromboembolism in thrombophilic families is not increased by high thrombin-activatable fibrinolysis inhibitor (TAFI) levels.

Folkeringa N, Coppens M, Veeger NJ, Bom VJ, Middeldorp S, Hamulyak K, Prins MH, Büller HR, van der Meer J.

Thromb Haemost. 2008 Jul;100(1):38-44. doi: 10.1160/TH07-11-0659.

PMID:
18612536
3.

Co-segregation of thrombophilic disorders in factor V Leiden carriers; the contributions of factor VIII, factor XI, thrombin activatable fibrinolysis inhibitor and lipoprotein(a) to the absolute risk of venous thromboembolism.

Libourel EJ, Bank I, Meinardi JR, Baljé -Volkers CP, Hamulyak K, Middeldorp S, Koopman MM, van Pampus EC, Prins MH, Büller HR, van der Meer J.

Haematologica. 2002 Oct;87(10):1068-73.

4.

The risk of recurrent venous thromboembolism among patients with high factor IX levels.

Weltermann A, Eichinger S, Bialonczyk C, Minar E, Hirschl M, Quehenberger P, Schönauer V, Kyrle PA.

J Thromb Haemost. 2003 Jan;1(1):28-32.

5.

Circulating P-selectin and the risk of recurrent venous thromboembolism.

Kyrle PA, Hron G, Eichinger S, Wagner O.

Thromb Haemost. 2007 Jun;97(6):880-3.

PMID:
17549288
6.

Tissue factor pathway inhibitor and the risk of recurrent venous thromboembolism.

Hoke M, Kyrle PA, Minar E, Bialonzcyk C, Hirschl M, Schneider B, Kollars M, Weltermann A, Eichinger S.

Thromb Haemost. 2005 Oct;94(4):787-90.

PMID:
16270631
7.

High plasma levels of factor VIII and risk of recurrence of venous thromboembolism.

Cristina L, Benilde C, Michela C, Mirella F, Giuliana G, Gualtiero P.

Br J Haematol. 2004 Feb;124(4):504-10.

PMID:
14984502
8.

Thrombin activatable fibrinolysis inhibitor and the risk for deep vein thrombosis.

van Tilburg NH, Rosendaal FR, Bertina RM.

Blood. 2000 May 1;95(9):2855-9.

9.

High plasma levels of factor VIII and the risk of recurrent venous thromboembolism.

Kyrle PA, Minar E, Hirschl M, Bialonczyk C, Stain M, Schneider B, Weltermann A, Speiser W, Lechner K, Eichinger S.

N Engl J Med. 2000 Aug 17;343(7):457-62.

10.

High functional levels of thrombin-activatable fibrinolysis inhibitor are associated with an increased risk of first ischemic stroke.

Leebeek FW, Goor MP, Guimaraes AH, Brouwers GJ, Maat MP, Dippel DW, Rijken DC.

J Thromb Haemost. 2005 Oct;3(10):2211-8. Epub 2005 Jul 8.

11.

[Thrombin-activated inhibitor of fibrinolysis and efficacy and safety of long-term warfarin treatment in patients with venous thromboembolic complications].

Vorob'eva NM, Panchenko EP, Dobrovol'skiĭ AB, Titaeva EV, Ermolina OV, Balakhonova TV, Khasanova ZB, Postnov AIu, Kirienko AI.

Ter Arkh. 2011;83(12):43-8. Russian.

PMID:
22416444
12.

Low vitamin B6 levels and the risk of recurrent venous thromboembolism.

Hron G, Lombardi R, Eichinger S, Lecchi A, Kyrle PA, Cattaneo M.

Haematologica. 2007 Sep;92(9):1250-3. Epub 2007 Aug 1.

13.

Venous thrombosis risk associated with plasma hypofibrinolysis is explained by elevated plasma levels of TAFI and PAI-1.

Meltzer ME, Lisman T, de Groot PG, Meijers JC, le Cessie S, Doggen CJ, Rosendaal FR.

Blood. 2010 Jul 8;116(1):113-21. doi: 10.1182/blood-2010-02-267740. Epub 2010 Apr 12.

14.

Overweight, obesity, and the risk of recurrent venous thromboembolism.

Eichinger S, Hron G, Bialonczyk C, Hirschl M, Minar E, Wagner O, Heinze G, Kyrle PA.

Arch Intern Med. 2008 Aug 11;168(15):1678-83. doi: 10.1001/archinte.168.15.1678.

PMID:
18695082
15.

The effect of genetic variants in the thrombin activatable fibrinolysis inhibitor (TAFI) gene on TAFI-antigen levels, clot lysis time and the risk of venous thrombosis.

Martini CH, Brandts A, de Bruijne EL, van Hylckama Vlieg A, Leebeek FW, Lisman T, Rosendaal FR.

Br J Haematol. 2006 Jul;134(1):92-4.

PMID:
16803573
16.

The post-thrombotic syndrome: risk factors and impact on the course of thrombotic disease.

Stain M, Schönauer V, Minar E, Bialonczyk C, Hirschl M, Weltermann A, Kyrle PA, Eichinger S.

J Thromb Haemost. 2005 Dec;3(12):2671-6.

17.

Poor anticoagulation quality in the first 3 months after unprovoked venous thromboembolism is a risk factor for long-term recurrence.

Palareti G, Legnani C, Cosmi B, Guazzaloca G, Cini M, Mattarozzi S.

J Thromb Haemost. 2005 May;3(5):955-61.

18.

D-dimer, factor VIII coagulant activity, low-intensity warfarin and the risk of recurrent venous thromboembolism.

Shrivastava S, Ridker PM, Glynn RJ, Goldhaber SZ, Moll S, Bounameaux H, Bauer KA, Kessler CM, Cushman M.

J Thromb Haemost. 2006 Jun;4(6):1208-14.

19.

Hyperhomocysteinemia is a risk factor of recurrent venous thromboembolism.

Eichinger S, Stümpflen A, Hirschl M, Bialonczyk C, Herkner K, Stain M, Schneider B, Pabinger I, Lechner K, Kyrle PA.

Thromb Haemost. 1998 Oct;80(4):566-9.

PMID:
9798970
20.

Coagulation factors, inflammation markers, and venous thromboembolism: the longitudinal investigation of thromboembolism etiology (LITE).

Tsai AW, Cushman M, Rosamond WD, Heckbert SR, Tracy RP, Aleksic N, Folsom AR.

Am J Med. 2002 Dec 1;113(8):636-42.

PMID:
12505113

Supplemental Content

Support Center